WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its selective SMARCA2 and KAT6A degraders. These groundbreaking therapies demonstrate strong potential to address unmet needs in cancer treatment.
The presentation highlighted PRT3789, the company’s first-in-class, highly selective SMARCA2 degrader currently in early clinical trials. Data revealed that PRT3789 achieves deep and sustained SMARCA2 degradation, offering a favorable safety profile and broad therapeutic index for patients with SMARCA4-mutated cancers. According to Peggy Scherle, Ph.D., Prelude’s Chief Scientific Officer, “We are pleased to provide further preclinical data on the discovery of our lead selective SMARCA2 degrader PRT3789, currently advancing in early clinical development for patients with SMARCA4 mutated cancers.”
Prelude also shared preclinical data on its selective KAT6A degraders, which are designed to improve efficacy and safety compared to existing non-selective KAT6A/B inhibitors. The study demonstrated that these oral degraders delivered robust anti-cancer activity in breast and lung cancer models, with reduced toxicity and deep tumor regression. “These data demonstrate that selectively degrading KAT6A results in robust anti-cancer activity in various pre-clinical models,” Scherle noted, adding that this innovation addresses safety challenges while expanding therapeutic options.
Key Findings
- PRT3789 (SMARCA2 Degrader): Enables selective ubiquitination, stabilizes a critical protein complex, and slows the resynthesis rate of SMARCA2, enhancing its safety and efficacy for advanced solid tumors. PRT3789 is currently in Phase 1 and Phase 2 trials.
- KAT6A Degraders: Offer a targeted protein degradation approach, showing superior anti-cancer responses across multiple tumor types, reduced hematologic toxicity, and significant combination benefits with standard-of-care therapies.
The promising results reflect Prelude’s commitment to advancing novel therapeutic candidates that target clinically validated pathways with precision. Looking ahead, the company remains focused on building its pipeline of first-in-class oncology treatments to address significant unmet medical needs and improve patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.